Ryplazim® (plasminogen, human-tvmh) – New orphan drug approval
June 4, 2021 - The FDA announced the approval of Liminal BioSciences’ Ryplazim (plasminogen, human-tvmh), for the treatment of patients with plasminogen deficiency type 1 (hypoplasminogenemia).
Download PDF
